Cost-Effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage

Abstract

Background and Purpose-Intracerebral hemorrhage (ICH) is among the most costly and debilitating forms of stroke.Results from a recent Phase IIb clinical trial demonstrate that administration of recombinant activated factor VII (rFVIIa) reduces ICH mortality and improves functional outcome. In the current analysis, we examine the cost-effectiveness of early treatment with rFVIIa for ICH in the United States. Methods-A decision-analytic model was developed to estimate the lifetime costs and outcomes associated with rFVIIa treatment at doses of 40, 80 and 160 g/kg compared with current standard of care in treating ICH, from a US third-party payer perspective. The patient population was similar to that of the Phase IIb clinical trial. Model structure and inputs were obtained from published literature, clinical trial data, claims databases, and expert opinion. All costs are presented in 2005 US dollars. Outcomes included incremental cost per life-year (LY) saved and incremental cost per quality-adjusted life-year (QALY) gained. Costs and outcomes were discounted at 3% annually. Univariate and multivariate sensitivity analyses were conducted to assess model robustness. Results-Compared with standard care, treatment with rFVIIa 40 g/kg, and 160 g/kg results in total lifetime cost-effectiveness ratios of $6308/QALY and $3152/QALY, respectively. Treatment with rFVIIa 80 g/kg was found to be cost saving and a gain of 1.67 QALYs is achieved over a patient's lifetime. These results are robust to changes in input parameters. Conclusions-Treatment of ICH with rFVIIa 40 g/kg and 160 g/kg appears to be cost-effective (Յ$50 000/QALY). At the 80 g/kg dose, rFVIIa was not only cost-effective, but also cost saving. (Stroke. 2006;37:2751-2758.)

The Cost of Pediatric Stroke Care and Rehabilitation

“…Many analyses of the cost of adult stroke care have been conducted, and one aspect of these analyses, cost analysis, has been used to evaluate the efficacy of adult stroke treatments. [37][38][39][40] Analysis of pediatric stroke care could be used as one parameter to measure the effectiveness of treatment options. Recent calls for multicenter clinical trials of pediatric stroke 41,42 raise the possibility that opportunities will exist to examine cost data prospectively.…”

The cost-effectiveness of telestroke in the treatment of acute ischemic stroke

“…The utility weight associated with mRS scores used here was obtained from a previous study 26 and has been used in several other cost-effectiveness analyses of stroke. 27,28 We measured overall cost-effectiveness using the incremental cost-effectiveness ratio (ICER), which is calculated by dividing the difference in average costs per patient between telestroke and usual care by the difference in average QALYs per patient between telestroke and usual care.…”

A Cost–Utility Analysis of Mechanical Thrombectomy as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Large-Vessel Ischemic Stroke

“…We used median utility for mild strokes (0.85) and an average for moderate and major strokes (0.27) as baseline utilities for independent and dependent health states. 19,21 For estimating annual mortality, we multiplied age-specific all-cause mortality rates from the 2006 United States Centers for Disease Control and Prevention life tables 22 by the relative risk of death for persons with independent (1.96) and dependent functional status (3.73) after neurological injury. 23 …”